Magstim TMS Efficacy

Clinical trials have shown that TMS Therapy may help to reduce or diminish symptoms of depression after 4 to 6 weeks of treatment. Magstim Horizon TMS Therapy systems are indicated for the treatment of major depressive disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. These systems are FDA-approved for standard treatment at 10Hz and for intermittent theta beta burst stimulation.

An Effective and Durable Option for Treating Major Depressive Disorder

With MDD there are biological alterations in the brain, including an imbalance of activity in frontal brain regions.1 These areas of the brain are involved in important mental processes and also have connections with deeper brain regions responsible for emotions.2 Due to the ability of rTMS to alter brain activity, it was first proposed as a therapy for MDD in the mid-1990s3. Since then, numerous studies have demonstrated the safety and effectiveness of rTMS in MDD, especially in treatment-resistant patients who have not responded to antidepressants4.

Approximately 58% of treatment-resistant patients respond positively to rTMS therapy5.

TMS+YOU is an online community and national patient advocacy site for TMS Therapy. Those considering Transcranial Magnetic Stimulation can connect with patients who have had the treatment to answer questions, share insights, and get the latest information.

 

References:

  1. Henriques, J. B., & Davidson, R. J. (1991). Left frontal hypoactivation in depression. Journal of abnormal psychology, 100(4), 535.
  2. De Raedt, R., Vanderhasselt, M. A., & Baeken, C. (2015). Neurostimulation as an intervention for treatment resistant depression: From research on mechanisms towards targeted neurocognitive strategies. Clinical Psychology Review, 41, 61-69.
  3. Höflich, G., Kasper, S., Hufnagel, A., Ruhrmann, S., & Möller, H. J. (1993). Application of transcranial magnetic stimulation in treatment of drug‐resistant major depression—a report of two cases. Human Psychopharmacology: Clinical and Experimental, 8(5), 361-365.
  4. Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., … & Lohr, K. N. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry, 75(5), 477-489.
  5. Carpenter, L. L., Janicak, P. G., Aaronson, S. T., Boyadjis, T., Brock, D. G., Cook, I. A., … & Demitrack, M. A. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and anxiety, 29(7), 587-596.

we want to hear from you